|
Decision Resources' analysts are the leading experts on various healthcare issues. From specific drug market analysis to insights on industry trends, Decision Resources' analysts are available to speak with journalists on almost any topic.
For media inquiries or to speak with an analyst, please contact:
Elizabeth Marshall
+1-781-296-2563
emarshall@dresources.com
November
[ Back to Top ]
November
19,
2008
UPTAKE OF NEXT-GENERATION ANTIFUNGALS HAS INTENSIFIED COMPETITION IN THE SEVERE FUNGAL INFECTIONS DRUG MARKET
However, Generic Erosion and a Dearth of Promising Emerging Therapies Will Result in Modest Annual Growth, According to a New Report from Decision Resources
More...
November
17,
2008
CHINA’S MAJOR DEPRESSION DRUG MARKET WILL TRIPLE BY 2012
Physicians and Patients Prefer Western-Branded Drugs to Chinese-Manufactured Products, According to a Report from Decision Resources
More...
November
17,
2008
MOST PROMISING EMERGING VACCINES INCLUDE NOVARTIS’S MenB AND WYETH’S PCV13 AS COMBINED PEAK-YEAR SALES COULD EXCEED $4 BILLION BY 2022
Pneumococcal and Meningococcal Diseases as well as Human Papillomavirus Represent Highest Value Vaccine Sectors Over Next 15 years, According to a New Report from Decision Resources
More...
November
12,
2008
ADVAIR IS POSITIONED AHEAD OF SPIRIVA IN FIRST- AND SECOND-LINES OF THERAPY FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Symbicort Will Be Used More Frequently in Second-Line Therapy Over the Next Two Years, According to a New Report from Decision Resources
More...
November
12,
2008
GILEAD TO TOPPLE GSK AS THE TOP PLAYER IN THE ANTI-INFECTIVES DRUG MARKET IN 2014
Stringent, Yet Ill-Defined, Approval Standards Make it Difficult for Companies to Bring Hospital Antibiotics to Market, According to a New Report from
Decision Resources
More...
November
7,
2008
RHEUMATOLOGISTS ANTICIPATE USING ORENCIA AND RITUXAN MORE FREQUENTLY IN FIRST- AND SECOND-LINE THERAPY FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Fewer Patients Start Enbrel After Another TNF-Alpha Inhibitor Versus Humira or Remicade, According to a New Report from Decision Resources
More...
November
6,
2008
PROMOTION OF MERCK/SCHERING-PLOUGH’S VYTORIN AS A FIRST-LINE AGENT HAS BEEN COMPROMISED BY NEGATIVE PRESS
Lipitor’s Abstract Tagline Fails to Resonate with Physicians, According to a New Report from Decision Resources
More...
November
5,
2008
PHYSICIANS RANK SCHERING-PLOUGH’S MARKETING MESSAGES FOR ASMANEX AS THE MOST APPEALING IN THE ASTHMA DRUG MARKET
Patients Respond Most Favorably to the Marketing Messages for Advair and Xolair, According to a New Report from Decision Resources
More...
November
5,
2008
DECISION RESOURCES’ WHITE PAPER DISCUSSES INCREASING REALITY OF BIOSIMILARS AND THEIR IMPACT ON BIOLOGICS MARKET
From Biologics to Biosimilars—How Will the Market Evolve?
More...
November
4,
2008
ACTIVITY AGAINST MRSA IS THE MOST IMPORTANT ATTRIBUTE INFLUENCING PHYSICIANS’ ANTIBIOTIC SELECTION FOR THE TREATMENT OF SKIN AND SKIN STRUCTURE INFECTIONS
Success of Zyvox and Cubicin is Driven Strongly by Agents’ Excellent Activity Against MRSA, According to a New Report from AMR and Decision Resources
More...
November
3,
2008
THE MEDICARE HOSPITAL-ACQUIRED CONDITIONS INITIATIVE WILL SPUR INCREASED PATIENT SCREENING AND POTENTIALLY INCREASED ANTIBIOTIC USE
Majority of Physicians are Most Concerned About Lack of Reimbursement for Vascular Catheter-Associated Infections, According to a New Report from Decision Resources
More...
October
[ Back to Top ]
October
27,
2008
HUMIRA TO REPLACE REMICADE AS FIRST CHOICE AMONG BIOLOGICS FOR THE TREATMENT OF CROHN’S DISEASE
Oral 5-Aminosalicylates Will Continue to be Used in Early Lines of Therapy,
According to a New Report from Decision Resources
More...
October
27,
2008
TOP 10 THINGS PHARMA SHOULD KNOW ABOUT INDIA – FREE PAPER FROM DECISION RESOURCES
Competition From Alternative Medicine and Relationships With Healthcare Facilities Are Among the Issues Detailed in the Paper
More...
October
22,
2008
THE PHARMACEUTICAL INDUSTRY AND THE ELECTION – NEW REPORT AVAILABLE FOR FREE FROM DECISION RESOURCES
Pharma Industry Donations to Democratic Candidates Outpacing Those to Republicans
More...
October
21,
2008
GENENTECH/ROCHE/CHUGAI’S AVASTIN WILL GARNER MORE THAN 20 PERCENT OF THE TOTAL BREAST CANCER DRUG MARKET IN 2017
Significant Unmet Need Remains for Agents that are Effective in Treating Triple-Negative Breast Cancer, According to a New Report from Decision Resources
More...
October
20,
2008
ROBUST 3.6 PERCENT ANNUAL GROWTH IN THE NON-HODGKIN’S LYMPHOMA DRUG MARKET WILL BE DRIVEN BY THE CONTINUED DOMINANCE OF RITUXAN/MABTHERA
Ofatumumab Will Garner Impressive Sales But Will Not Take Significant Patient Share from Rituxan/MabThera, According to a New Report from Decision Resources
More...
October
15,
2008
PREVALENCE OF TYPE 2 DIABETES IN INDIA IS AMONG THE HIGHEST IN THE WORLD AND GROWING
Insulins and Other Expensive Agents Are Out of Reach of Most Indian Patients, According to a Report From Decision Resources
More...
October
15,
2008
MAJOR DEPRESSION PREVALENCE IS CLOSELY CORRELATED WITH ETHNIC STATUS IN THE U.S.
California, Texas, Arizona and Florida Are Four of the Five States
With the Lowest Prevalent Rates of Depression, According to a New Analytics Tool From Decision Resources
More...
October
15,
2008
DECISION RESOURCES, INC. NAMED TO THE INC. 5000 LIST
Organic Growth and Acquisitions Have Driven the Company’s Development
More...
October
14,
2008
BIOSIMILAR MONOCLONAL ANTIBODIES IN ONCOLOGY WILL APPROACH BLOCKBUSTER STATUS BY 2017
Opportunity for Biosimilars Varies Significantly by Therapeutic Area, According to a New Report from Decision Resources
More...
October
14,
2008
SURVEYED ONCOLOGISTS SAY THAT THE MOST PROMISING TARGETED THERAPY IN ADJUVANT CLINICAL TRIALS IS AVASTIN FOR THE TREATMENT OF EARLY-STAGE COLORECTAL CANCER
Despite Widespread Use, Formulary Coverage of Targeted Cancer Therapies is Inconsistent, According to a New Report from Decision Resources
More...
October
8,
2008
THE MARKET FOR DISEASE-MODIFYING OSTEOARTHRITIS DRUGS WILL EXPERIENCE EXPONENTIAL GROWTH, INCREASING FROM $477 MILLION IN 2007 TO NEARLY $3.8 BILLION IN 2017
Extensive Need for Disease-Modifying Agents Creates Significant Opportunity for Drug Developers, According to a New Report from Decision Resources
More...
October
7,
2008
LAUNCH OF NEW DRUGS AND INCREASED UPTAKE OF CURRENT AGENTS WILL DRIVE ROBUST ANNUAL 5.2 PERCENT GROWTH IN THE NEUROPATHIC PAIN MARKET
Significant Opportunity Exists for Second-Line Therapies in Neuropathic Pain Market, According to a New Report from Decision Resources
More...
October
7,
2008
INDIA’S HEPATITIS C VIRUS DRUG MARKET WILL GROW TO MORE THAN $171 MILLION BY 2012
Familiarity With Drug Treatment Options Will Vary By Region and Clinical Experience, According to a Report From Decision Resources
More...
September
[ Back to Top ]
September
29,
2008
THE CENTRAL NERVOUS SYSTEM IS THE NEXT DISEASE MARKET WHERE BIOMARKERS WILL HAVE THE GREATEST IMPACT
A Biomarker for the Diagnosis of Alzheimer’s Disease Will Have the Largest Impact on Drug Sales Among the CNS Markets, According to a New Report from Decision Resources
More...
September
29,
2008
SHIRE’S VYVANSE WILL ATTAIN BLOCKBUSTER STATUS BY 2017 IN THE ATTENTION-DEFICIT/HYPERACTIVITY DISORDER DRUG MARKET
Emerging Nonstimulant Drugs Will Earn Less Than 15 Percent Share of the ADHD Market in 2017, According to a New Report from Decision Resources
More...
September
23,
2008
GENERIC EROSION AND A DEARTH OF INNOVATIVE EMERGING THERAPIES WILL CONSTRAIN THE ATOPIC DERMATITIS DRUG MARKET THROUGH 2017
Physicians Continue to Seek an Effective Maintenance Therapy to Treat the Disorder, According to a New Report from Decision Resources
More...
September
22,
2008
RHEUMATOID ARTHRITIS PREVALENCE IS LOWER AMONG ASIANS AND HIGHER AMONG AMERICAN INDIANS, COMPARED WITH BLACKS AND WHITES IN THE U.S.
Eastern Seaboard Has Seven of the Eight Regions with the Highest Prevalence in the U.S., According to a New Analytics Tool From Decision Resources
More...
September
22,
2008
PHYSICIANS ESTIMATE THAT IF APPROVED, CEFTOBIPROLE WILL STEAL NEARLY A THIRD OF ZYVOX’S PATIENT SHARE IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA
Most Important Factors Driving Nosocomial Pneumonia Prescribing in Hospitals Are Infectious Disease Consults and ATS/IDSA Guidelines
More...
September
22,
2008
SALES OF ANTICOAGULANTS FOR THE TREATMENT OF ST-ELEVATION MYOCARDIAL INFARCTION WILL DOUBLE OVER THE NEXT 10 YEARS
Percutaneous Coronary Intervention Has Become More Widely Available to Patients in Recent Years, According to a New Report from Decision Resources
More...
September
18,
2008
DERMATOLOGISTS CONTINUE TO USE ENBREL OVER HUMIRA AS FIRST-LINE BIOLOGIC THERAPY FOR THE TREATMENT OF PSORIASIS
More Than 60 Percent of Dermatologists Familiar with the Drug
Plan to Prescribe Stelara (Ustekinumab) Upon Its Anticipated Approval,
According to a New Report from Decision Resources
More...
September
17,
2008
METFORMIN, ACTOS AND JANUVIA ARE THE MOST COMMONLY PRESCRIBED AGENTS FOR THE TREATMENT OF PREDIABETES
Most Surveyed MCOs Allow Physicians a High Level of Prescribing Freedom for Treatment of Prediabetes, According to a New Report from Decision Resources
More...
September
16,
2008
OVER TWO-THIRDS OF SURVEYED MCO PHARMACY DIRECTORS CITE TNF-ALPHA INHIBITORS AND ERYTHROPOIESIS-STIMULATING PROTEINS AS TOP PRIORITY BIOLOGICS THEY WOULD REPLACE WITH BIOSIMILARS
Following the Establishment of a Regulatory Pathway for Biosimilars in the U.S., Amgen is Most Vulnerable to Biosimilar Threat, According to a New Report from Decision Resources
More...
September
15,
2008
CALIFORNIA SHOWS HIGH VARIABILITY IN TREATMENT RATES OF PSORIASIS
Los Angeles’ Near-Average Treatment Rate Presents Significant Opportunity for Pharmaceutical Companies, According to a New Analytics Tool From Decision Resources
More...
September
15,
2008
EMERGING THERAPIES, INCLUDING BRISTOL-MYERS SQUIBB/MEDAREX'S IPILIMUMAB, WILL DRIVE GROWTH IN THE MALIGNANT MELANOMA DRUG MARKET
Interviewed Experts Lack Confidence in Malignant Melanoma Cancer Vaccines as a Result of Recently Published Data, According to a New Report from Decision Resources
More...
September
9,
2008
GLAXOSMITHKLINE’S LAMICTAL WILL CONTINUE TO DOMINATE THE EPILEPSY DRUG MARKET OVER THE NEXT 10 YEARS
Market Will Experience Only Minimal Growth Through 2017, According to a New Report from Decision Resources
More...
September
9,
2008
ROBUST SALES OF INTEGRILIN, REOPRO AND AGGRASTAT WILL DRIVE THE UNSTABLE ANGINA/NON-ST-ELEVATION MYOCARDIAL INFARCTION DRUG MARKET
Premium Priced Drug Classes Account for 70 Percent of Market Sales, According to a New Report from Decision Resources
More...
September
8,
2008
CHINA’S HEPATITIS C VIRUS DRUG MARKET WILL GROW TO $150 MILLION BY 2012
Increasing Diagnosis Rates Present Opportunities for Western Drug Companies Seeking to Penetrate Market, According to a New Report From Decision Resources
More...
September
8,
2008
NOVEL ORAL ANTICOAGULANTS, PARTICULARLY BAYER/ORTHO-McNEIL’S XARELTO, WILL DRIVE ROBUST ANNUAL GROWTH IN THE VENOUS THROMBOEMBOLISM DRUG MARKET
Dominance of Low-Molecular-Weight Heparins and Vitamin K Antagonists Will Be Curtailed by Novel Drugs, According to a New Report from Decision Resources
More...
September
4,
2008
PHYSICIANS EAGER TO INCREASE THEIR FIRST- AND SECOND-LINE PRESCRIPTIONS FOR JANUVIA OVER THE NEXT TWO YEARS FOR THE TREATMENT OF TYPE 2 DIABETES
PPAR-Gamma Agonists’ Share of Second-Line Treatment is Declining,
According to a New Report from Decision Resources
More...
August
[ Back to Top ]
August
28,
2008
CHINA’S HEPATITIS B VIRUS DRUG MARKET WILL GROW TO $800 MILLION BY 2012
Competition From Chinese Makers Present Considerable Challenge to Branded Western Drug Companies Seeking to Penetrate Market, According to a New Report From Decision Resources
More...
August
28,
2008
FLORIDA IS STATE WITH HIGHEST PERCENTAGE OF UNTREATED PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Utah and Mississippi Rank Very Low in Treatment Rate for Asthma and Chronic Obstructive Pulmonary Disease, According to a New Analytics Tool From Decision Resources
More...
August
26,
2008
HALF OF SURVEYED PHYSICIANS EXPECT TO REPLACE BETWEEN 6 PERCENT AND 15 PERCENT OF THEIR SUSTIVA PRESCRIPTIONS WITH ISENTRESS
Most Surveyed MCO Pharmacy Directors Do Not Place Cost Control Measures on Branded Antiretroviral Drugs, According to a New Report from Decision Resources
More...
August
21,
2008
PHARMACOGENOMICS-BASED DRUG DEVELOPMENT HOLDS PROMISE FOR PHARMA INDUSTRY’S DECADE-LONG SLIDE
Personalized Medicine Has the Potential for Good and Bad,
According to a New Report from Decision Resources
More...
August
18,
2008
INDIA’S HEPATITIS B VIRUS DRUG MARKET WILL GROW TEN-FOLD BY 2012
Physician Treatment Patterns and Drivers Will Vary Based on a Drug’s Safety, Efficacy and Cost
More...
August
14,
2008
RELATIVE TO THEIR POPULATION SIZE, NEW ENGLAND STATES SHOULD SUPPORT LARGEST MARKETS FOR DYSLIPIDEMIA DRUGS
Massachusetts, Maine and Vermont Have the Highest Percentages of Dyslipidemia Patients Who Have Prescription Drug Coverage but Are Currently Untreated, According to a New Analytics Tool From Decision Resources
More...
August
13,
2008
LAUNCHES OF HUMIRA, GOLIMUMAB AND ORENCIA FOR TREATMENT OF ULCERATIVE COLITIS WILL DRIVE ANNUAL FIVE PERCENT MARKET GROWTH
Expected Approvals of Biologic Agents Will Expand Treatment Options for Patients Who Fail Conventional Drug Treatment, According to a New Report from Decision Resources
More...
August
12,
2008
INSULIN ANALOGUES FROM NOVO NORDISK, ELI LILLY AND SANOFI-AVENTIS WILL DRIVE GROWTH IN THE TYPE 1 DIABETES DRUG MARKET
Owing to Well-Established and Effective Insulin-Based Therapies, Market Growth Will be Modest Through 2017, According to a New Report from Decision Resources
More...
August
11,
2008
FLORIDA IS THE STATE WITH THE HIGHEST NUMBER OF TYPE 2 DIABETICS WHO HAVE PRESCRIPTION DRUG COVERAGE BUT ARE CURRENTLY UNTREATED
Decision Resources Introduces the Only Healthcare Analytics Tool that Assesses the Number of Insured Patients Who Have a Specific Disease, but Are Untreated
More...
August
11,
2008
ASTONISHING 52 PERCENT OF NEWLY DIAGNOSED BIPOLAR DISORDER PATIENTS RECEIVE ANTIDEPRESSANT DRUGS IN FIRST-LINE TREATMENT
Lamictal Is the Leading Single-Agent in First-, Second- and Third-Line Therapy, According to a New Report from Decision Resources
More...
August
6,
2008
EIGHTY-NINE PERCENT OF SURVEYED RHEUMATOLOGISTS SAY THEY WILL PRESCRIBE ROCHE/CHUGAI’S ACTEMRA FOR RHEUMATOID ARTHRITIS
However, Pharmacy Directors Disagree About Formulary Inclusion for Key Emerging Biologic Agents That Will Launch for the Disease in the Next Few Years, According to a New Report from Decision Resources
More...
August
5,
2008
SALES OF EMERGING NOVEL PAIN THERAPIES WILL REPRESENT MORE THAN ONE-FIFTH OF THE TOTAL PAIN DRUG MARKET BY 2023
Total Drug Market for Pain Will Reach More Than $47 Billion in 2023, According to a New Report from Decision Resources
More...
July
[ Back to Top ]
July
29,
2008
A HIGH-DENSITY LIPOPROTEIN RAISING DRUG THAT HAS A LOWER DISCONTINUATION RATE THAN THAT OF EXTENDED RELEASE NIASPAN WOULD EARN A 20 PERCENT PATIENT SHARE IN THE DYSLIPIDEMIA DRUG MARKET
Crestor Will Remain the Clinical Gold Standard Drug Through 2016, According to a New Report from Decision Resources
More...
July
24,
2008
LORI SILVER JOINS DECISION RESOURCES, INC. AS GENERAL COUNSEL
Formerly of Harvard University’s Office of General Counsel, Attorney Will be Responsible for All Legal Aspects of the Company
More...
July
22,
2008
A DRUG THAT IMPROVES EXERCISE CAPACITY BY A GREATER PERCENTAGE THAN TRACLEER WOULD EARN A 48 PERCENT PATIENT SHARE IN THE PULMONARY ARTERIAL HYPERTENSION MARKET
Gleevec Will Achieve Clinical Gold Standard Status by 2011, According to a New Report from Decision Resources
More...
July
17,
2008
ONLY 44.4 PERCENT OF PARKINSON’S DISEASE PATIENTS RECEIVE DRUG TREATMENT WITHIN ONE YEAR OF BEING DIAGNOSED
Few First-Line Patients Receive Dopamine Agonists Despite These Agents’ Ability to Stave Off Levodopa Treatment, According to a New Report from Decision Resources
More...
July
15,
2008
BAPINEUZUMAB TO BECOME THE FIRST-TO-MARKET DISEASE-MODIFYING ALZHEIMER’S DRUG AFTER FLURIZAN’S DISCONTINUATION
Up-to-Date Analysis of the Alzheimer’s Disease Market Now Available from
Decision Resources
More...
July
15,
2008
CURRENT AND EMERGING DRUGS CONTINUE TO STRUGGLE FOR PATIENT SHARE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard Treatment, According to a New Report from Decision Resources
More...
July
14,
2008
UNITED STATES MARKET FOR THE TREATMENT OF PULMONARY SYMPTOMS OF CYSTIC FIBROSIS REACHED $397 MILLION IN 2007
Prevalence of the Disease Will Rise As Improved Treatments Increase Patient Longevity, According to a New Report from Decision Resources
More...
July
10,
2008
ALTHOUGH GENERIC EROSION LOOMS FOR RISPERDAL, THE DRUG REMAINS FIRST-LINE ANTIPSYCHOTIC IN THE TREATMENT OF SCHIZOPHRENIA
Other Atypicals Thrive by Capturing Specific Patient Populations, According to a New Report from Decision Resources
More...
July
9,
2008
PRIMARY CARE PHYSICIANS’ PRESCRIPTIONS OF ARICEPT FOR ALZHEIMER’S DISEASE WILL DROP BY 20 PERCENT FOLLOWING THE AVAILABILITY OF GENERIC RAZADYNE IN DECEMBER 2008
Most Surveyed MCO Pharmacy Directors Will Move Razadyne and Razadyne ER from Tier 2 to Tier 3 When Generic Razadyne is Launched, According to a New Report from Decision Resources
More...
July
1,
2008
A WEIGHT NEUTRAL ORAL ANTIDIABETIC DRUG WOULD EARN A 25 PERCENT PATIENT SHARE IN THE TYPE 2 DIABETES DRUG MARKET
Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources
More...
June
[ Back to Top ]
June
26,
2008
BECAUSE OF ITS ABILITY TO GENERATE HIGHER TOTAL SALES IN THE UNITED STATES AND EUROPE, LUCENTIS WILL EARN CLINICAL GOLD STANDARD STATUS BY 2011 FOR THE TREATMENT OF DIABETIC RETINOPATHY
A Drug with Superior Efficacy to Avastin at Improving Visual Acuity When Used with Laser Photocoagulation Would Earn a 20 Percent Patient Share, According to a New Report from Decision Resources
More...
June
25,
2008
CHINA’S RENAL CELL CARCINOMA DRUG MARKET WILL GROW MORE THAN FIVE-FOLD BY 2012
Physician Treatment Patterns and Drivers Will Vary by Geographic Location, According to a New Report by Decision Resources
More...
June
24,
2008
RENAL CELL CARCINOMA DRUG MARKET WILL MORE THAN DOUBLE OVER THE NEXT DECADE, RISING FROM $625 MILLION IN 2007 TO NEARLY $1.6 BILLION IN 2017
Multikinase Inhibitors, Most Notably Pfizer’s Sutent, Will Continue to Dominate the Market, According to a New Report from Decision Resources
More...
June
19,
2008
NOVEL AGENTS WILL DRIVE THE HEPATITIS C VIRUS DRUG MARKET TO INCREASE NEARLY FIVE-FOLD TO MORE THAN $10 BILLION IN 2017
Hepatitis C Virus Market is One of the Most Active Areas of Infectious Disease Drug Development in Recent Years, According to a New Report from Decision Resources
More...
June
18,
2008
LEXAPRO IS THE LEADING SINGLE AGENT IN FIRST- AND SECOND-LINE PATIENT SHARE FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDER
The Presence of Comorbid Depression Influences Physicians to Prescribe a Selective Serotonin Reuptake Inhibitor, According to a New Report from Decision Resources
More...
June
18,
2008
LUNDBECK MAINTAINING PRESENCE IN ALZHEIMER’S DISEASE MARKET THROUGH STRATEGIC AGREEMENT TO MARKET MYRIAD GENETICS’ FLURIZAN
Physician Education Will be a Critical Step in the Adoption of Emerging Alzheimer’s Disease Therapies, According to a New Report from Decision Resources
More...
June
17,
2008
GENERIC EROSION OF MARKET LEADING THERAPIES WILL CONSTRAIN GROWTH IN THE PARKINSON’S DISEASE DRUG MARKET OVER THE NEXT DECADE
Modest Market Growth Will be Driven by the Arrival of Once-Daily Formulations of Dopamine Agonists, According to a New Report from Decision Resources
More...
June
17,
2008
DECISION RESOURCES, INC. ACQUIRES MANHATTAN RESEARCH
Acquisition Expands Decision Resources, Inc.’s Portfolio to Include Global
Physician and Consumer Digital Market Research
More...
June
16,
2008
GOLIMUMAB AND ACTEMRA WILL BE TWO OF THE MOST SUCCESSFUL EMERGING NOVEL AGENTS IN THE RHEUMATOID ARTHRITIS DRUG TREATMENT MARKET
Among Currently Available Therapies, Enbrel and Humira Will Continue to Dominate the Market Through 2017, According to a New Report from Decision Resources
More...
June
12,
2008
A DRUG WITH EFFICACY SUPERIOR TO THAT OF XENICAL AT INDUCING WEIGHT LOSS WOULD EARN A 40 PERCENT PATIENT SHARE IN THE OBESITY DRUG MARKET
Advantages in Efficacy and Delivery Will Make Qnexa the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources
More...
June
11,
2008
A DRUG WITH EFFICACY SUPERIOR TO THAT OF REMICADE AT INDUCING CLOSURE AND HEALING OF FISTULAS WOULD EARN A 30 PERCENT PATIENT SHARE IN THE CROHN’S DISEASE DRUG MARKET
Ustekinumab Will Earn a 5.4 Percent Patient Share by 2012, According to a New Report from Decision Resources
More...
June
10,
2008
THE MONOCLONAL ANTIBODIES DRUG MARKET FOR THE TREATMENT OF CANCER WILL MORE THAN DOUBLE TO $16.7 BILLION BY 2016
Market Will be Driven by Increasing Use of Established Agents That Include Avastin, Erbitux, Rituxan/MabThera, According to a New Report from Decision Resources
More...
June
9,
2008
EMERGENCE OF DRUGS FROM ELAN/WYETH, ELI LILLY, MYRIAD GENETICS AND MEDIVATION WILL DRIVE THE ALZHEIMER’S DISEASE DRUG MARKET TO NEARLY TRIPLE BY 2017
Sales of Currently Dominant Acetylcholinesterase Inhibitors Will Decrease by Nearly Half Over the Next Decade, According to a New Report from Decision Resources
More...
June
3,
2008
DESPITE AVAILABILITY OF NUMEROUS GENERIC ANTIDEPRESSANTS, FOREST LABORATORIES’ LEXAPRO RETAINS LEADERSHIP AMONG FIRST-LINE THERAPIES IN THE TREATMENT OF MAJOR DEPRESSION
Wyeth’s Pristiq to Benefit from Key Change in Physicians’ Prescribing Patterns, According to a New Report from Decision Resources
More...
June
3,
2008
GENERIC EROSION WILL CONSTRAIN PROSTATE CANCER DRUG MARKET, RESULTING IN ANNUAL MARKET GROWTH OF LESS THAN 2 PERCENT THROUGH 2012
However, Annual Market Growth Will Increase to 4.5 Percent from 2012 to 2017 Due to Emergence of Premium-Priced Drugs, According to a New Report from Decision Resources
More...
June
2,
2008
FLORIDA IS THE STATE WITH THE HIGHEST NUMBER OF TYPE 2 DIABETICS WHO HAVE PRESCRIPTION DRUG COVERAGE BUT ARE CURRENTLY UNTREATED
Decision Resources Introduces the Only Healthcare Analytics Tool that Assesses the Number of Insured Patients Who Have a Specific Disease, but Are Untreated
More...
June
2,
2008
DRIVEN BY THE USE OF PREMIUM-PRICED BRANDED AGENTS, THE HIV DRUG MARKET WILL EXPERIENCE ROBUST ANNUAL GROWTH THROUGH 2012
New Products From Novel Drug Classes Are Addressing Key Unmet Needs for Highly Treatment-Experienced Patients, According to a New Report from Decision Resources
More...
May
[ Back to Top ]
May
29,
2008
ORAL DRUG FROM NOVARTIS/MITSUBISHI TANABE WILL CAPTURE THE LARGEST MARKET SHARE OF ALL EMERGING MULTIPLE SCLEROSIS THERAPIES IN 2017
Overall Market Growth Will be Driven by Launch of Nine Emerging Therapies, Including Five Oral Agents, According to a New Report from Decision Resources
More...
May
28,
2008
EMERGING COMBINATION THERAPIES, INCLUDING DRUGS FROM NOVARTIS/SCHERING-PLOUGH AND GLAXOSMITHKLINE/THERAVANCE WILL DRIVE THE COPD DRUG MARKET TO MORE THAN $11 BILLION IN 2017
Prevalent COPD Population Will Rise by Nearly 19 Percent as a Result of Increased Diagnosis Rates, According to a New Report from Decision Resources
More...
May
28,
2008
CHINA’S TYPE 2 DIABETES DRUG MARKET WILL MORE THAN TRIPLE BY 2012
New Entries to China Drug Market to Garner More Than $270 Million in Combined Sales, According to a New Report by Decision Resources
More...
May
21,
2008
NOVEL GLYCOPEPTIDES AND CEPHALOSPORINS WILL DRIVE THE HOSPITAL-ACQUIRED INFECTIONS DRUG MARKET THROUGH 2017
Antibacterial Drug Development Faces Many Challenges Including Heightened Regulatory Scrutiny and Increasingly Stringent Reimbursement Policies, According to a New Report from Decision Resources
More...
May
19,
2008
INCREASED COMPETITION, GENERIC EROSION AND COST CONSCIOUSNESS WILL CAUSE ASTHMA DRUG MARKET TO DECLINE TO $10.1 BILLION IN 2017
However, Launch of New Agents Will Drive Growth in the Long-Acting Beta-Agonist/Inhaled Corticosteroid Class, According to a New Report from Decision Resources
More...
May
15,
2008
DAIICHI SANKYO/ELI LILLY’S EFFIENT AND ASTRAZENECA’S TICAGRELOR MAY OFFER ADVANTAGES IN THE TREATMENT OF POST-MYOCARDIAL INFARCTION
Considerable Opportunity Remains for an Antiplatelet Therapy that, Combined with Aspirin, Causes Less Bleeding than the Combination of Plavix/Iscover and Aspirin, According to a New Report from Decision Resources
More...
May
13,
2008
SIMVASTATIN LEADS PFIZER’S LIPITOR IN SECOND-LINE PATIENT SHARE FOR THE TREATMENT OF DYSLIPIDEMIA
Results from the ENHANCE Trial Impacting Physician Prescribing Patterns, According to a New Report from Decision Resources
More...
May
12,
2008
LAUNCHES OF AT LEAST 15 NEW BIOLOGIC THERAPIES BY 2017 WILL EXPAND TREATMENT OPTIONS FOR IMMUNE AND INFLAMMATORY DISEASES
High-Priced Emerging Immunomodulators Will Drive Robust Market Growth Over the Next Decade, According to a New Report from Decision Resources
More...
May
8,
2008
CURRENT AND EMERGING DRUGS HAVE NOT YET SHOWN AN ADVANTAGE IN SURVIVAL OVER VELCADE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA
A Drug Used in Combination with Velcade That Could Improve Overall Survival Would Earn a 45 Percent Patient Share, According to a New Report from Decision Resources
More...
April
[ Back to Top ]
April
24,
2008
AVASTIN USED IN COMBINATION WITH DRUGS FROM BRISTOL-MYERS SQUIBB HAS ADVANTAGES IN SURVIVAL RATES OVER THE CURRENT SALES-LEADING THERAPY FOR ADVANCED OVARIAN CANCER
Avastin Used in Combination with Taxol and Paraplatin Will Become the Clinical Gold Standard Treatment by 2011, According to a New Report from Decision Resources
More...
April
24,
2008
CURRENT AND EMERGING INSOMNIA DRUGS HAVE MINIMAL ADVANTAGES OVER SANOFI-AVENTIS’S AMBIEN IN CAUSING THE ONSET OF SLEEP
However, Somaxon’s Silenor Will Replace Ambien as the Clinical Gold Standard for Insomnia in 2011, According to a New Report from Decision Resources
More...
April
22,
2008
CONCERN FROM DOCTORS REGARDING THE CARDIOVASCULAR SAFETY OF GLAXOSMITHKLINE’S AVANDIA INCREASES NINE-FOLD FOLLOWING PUBLICATION OF META-ANALYSIS
Nearly Three-Quarters of Physicians Have Switched Patients to Merck’s Januvia, According to a New Report from Decision Resources
More...
April
22,
2008
A DRUG THAT CARRIES A LOWER RISK OF WEIGHT GAIN THAN ASTRAZENECA’S SEROQUEL AND HAS ANTIMANIC AND ANTIDEPRESSANT EFFECTS WOULD EARN A 30 PERCENT PATIENT SHARE IN BIPOLAR DISORDER TREATMENT
Seroquel’s Successor, Seroquel XR, Will Earn a 16 Percent Patient Share in the Bipolar Disorder Market by 2016, According to a New Report from Decision Resources
More...
April
17,
2008
TIER STATUS IN PRIVATE INSURANCE PLANS FOR OTHER ANTIPSYCHOTIC DRUGS WILL REMAIN LARGELY UNCHANGED FOLLOWING THE PATENT EXPIRY OF JANSSEN’S RISPERDAL
However, Up to 20 Percent of Surveyed MCO Medicaid Plans Will Remove Branded Antipsychotics From Formularies, According to a New Report from Decision Resources
More...
April
17,
2008
BAYER/SCHERING-PLOUGH/SHIONOGI’S AVELOX HAS ADVANTAGES OVER LEVOFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
Superior Bacteriological Eradication and Activity Against Antibiotic-Resistant Pathogens Earn Avelox Gold Standard Status Through 2016, According to a New Report from Decision Resources
More...
|
